English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAbout 8 to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems. Although many who have this condition — called monoclonal B-cell lymphocytosis (MBL) — do not experience any symptoms, a new study shows they may have an elevated risk for several health complications, including melanoma, a form of skin cancer.
Tag: Journal Of Clinical Oncology
Mayo Clinic researchers identify women with twice the risk of cancer in both breasts
Women with cancer in one breast may be at higher risk of developing cancer in the opposite breast if they are carriers of specific genetic changes that predispose them to develop breast cancer, according to a study led by the Mayo Clinic Comprehensive Cancer Center. The findings, published in the Journal of Clinical Oncology, will help personalize approaches to breast cancer screening and risk factors, study authors say.
ASCO22: Lung Cancer Therapy Could Help Patients Live Longer
Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug combination could extend the lives of those diagnosed with advanced non-small cell lung cancer, one of the most common forms of lung cancer. The research was presented today during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, with simultaneous publication in the peer-reviewed Journal of Clinical Oncology.
Mayo Clinic research suggests women over 65 be offered hereditary cancer genetic testing
A new study by Fergus Couch, Ph.D., of Mayo Clinic Cancer Center, along with collaborators from the CARRIERS consortium, suggests that most women with breast cancer diagnosed over 65 should be offered hereditary cancer genetic testing. The study was published Thursday, July 22, in the Journal of Clinical Oncology.
Validation of Novel Prognostic Index May Better Inform Burkitt Lymphoma Treatment
Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, today announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (BL-IPI) in patients with this rare, high-grade B-cell lymphoma that is often studied in trials with small sample sizes. This research has been published in the January 2021 online issue of Journal of Clinical Oncology.
OncoMX Knowledgebase Enables Research of Cancer Biomarkers and Related Evidence
Researchers at the George Washington University published a new knowledgebase and web portal, OncoMX, which will improve the exploration and research of cancer biomarkers in the context of related evidence.
Lenalidomide may delay onset of myeloma-related bone, organ damage
The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Results of the study, which was conducted by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute, were published Friday, Oct. 25, in the Journal of Clinical Oncology.